
The UK Competition and Markets Authority (CMA) announced this Wednesday its decision to clear Microsoft’s planned acquisition of artificial intelligence company Nuance Communications.
Although the CMA found that Nuance holds a “strong position in the supply of healthcare transcription software”, the watchdog found no reason for concern regarding competition in this sector following the proposed merger.
The competition regulator said it is not referring the merger to a Phase 2 investigation under the provisions of the Enterprise Act 2002. “Based on the available evidence, the CMA does not believe that the Merged Entity would have the ability to foreclose Microsoft’s rivals.”
“In particular, the CMA considers that the Merged Entity would not be able to foreclose rivals by bundling patient administration tools, patient engagement tools, or remote healthcare tools with healthcare transcription software”, it added.
It ultimately said that the combined offering of the two companies was unlikely to cause a “substantial lessening of competition in the UK in relation to conglomerate effects”, and would not be taking the investigation any further. The UK follows both the European Union and the United States competition authorities in clearing the deal.
Health transcription services are a mainstay of modern medical practice, taking health providers’ voice recordings and transcribing them into written – often electronic – formats. Such records are increasingly required for compliance, research, and other purposes, making this an attractive area for Artificial Intelligence developers such as Nuance.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Orders Apple to Address Fortnite App Block or Face Court Hearing
May 19, 2025 by
CPI
EU Civil Society Groups and Labor Unions Raise Alarm Over Proposed Changes to GDPR
May 19, 2025 by
CPI
EU Antitrust Regulators Push Back Deadline on UniCredit’s Takeover Bid for Banco BPM
May 19, 2025 by
CPI
Intel Challenges €376 Million EU Fine in Ongoing Antitrust Dispute
May 19, 2025 by
CPI
Red Bull Challenges EU Commission Over Lengthy Antitrust Inspection
May 19, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas